What is ANBC INC?
engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People's Republic of China.
SYUP · Verdict
Strong reward · low risk
SYUP scores well on balance sheet and growth with no major weaknesses flagged in the model.
Based on 88% data coverage
SYUP · Verdict
Interest covered 16081.2×
Revenue +295.6% CAGR
Above average
24% free-cash-flow margin
Above average
Model-based scoring. For information only — not financial advice.
engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People's Republic of China. Its products primarily include Qilisheng a product formulated to be a general health enhancer by fortifying the immune system; Qi-ju-di-huang, an oral solution that protects the kidney and the liver; Qing-re-jie-du, an oral solution that reduces fever and relieves heat; Sheng-mai-yin, a solution that protects energy and enhances body fluids; Xiao-qing-long, an oral solution that relieves cough and dyspnea; Shen-bao, a syrup for the treatment of impotence and spermatorrhoea; Ban-xia, a syrup that relieves cough; and Gan-mao-zhi-ke, a syrup that relieves flu symptoms, cough, and nasal congestion. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 23.88K.
The scoring profile indicates a strong reward potential, driven primarily by growth and valuation. Risk indicators are low, suggesting a relatively contained downside profile.
For informational purposes only. Not financial advice.